Bortezomib for Acute Antibody-mediated Rejection in Liver Transplantation

Overview

Journal Am J Transplant

Publisher Elsevier

Specialty General Surgery

Date 2012 Jun 12

PMID 22681986

Citations 23

Authors

F Paterno

M Shiller

G Tillery

J G OLeary

B Susskind

J Trotter

G B Klintmalm

Affiliations

Soon will be listed here.

Abstract

Antibody-mediated rejection (AMR) is an uncommon, but challenging type of rejection after solid organ transplantation. We review three cases of AMR in ABO-compatible liver transplant recipients. These cases were characterized by severe acute rejection resistant to steroids and antithymocyte globulin, histologic evidence of plasma cell infiltrates, C4d positivity and high serum anti-HLA donor-specific antibodies. All three patients were treated with bortezomib, a proteasome inhibitor effective in depleting plasma cells. After treatment, all patients had improved or normal liver function tests, resolution of C4d deposition and significant decline in their HLA donor-specific antibodies.

Citing Articles

Successful Use of Bortezomib for Recurrent Progressive Familial Intrahepatic Cholestasis Type II After Liver Transplantation: A Pediatric Case with a 9-Year Follow-Up.

Bak Y, Choi H, Kim Y, Oh S, Kim K Pediatr Gastroenterol Hepatol Nutr. 2024; 27(1):71-76.

PMID: 38249643 PMC: 10796264. DOI: 10.5223/pghn.2024.27.1.71.

Strategies for ABO Incompatible Liver Transplantation.

Jadaun S, Agarwal S, Gupta S, Saigal S J Clin Exp Hepatol. 2023; 13(4):698-706.

PMID: 37440942 PMC: 10333949. DOI: 10.1016/j.jceh.2022.12.008.

Acute Antibody-Mediated Rejection in Liver Transplant Recipients with Autoimmune Liver Disease: A Clinical and Pathologic Study of 4 Cases.

Jiang H, Guo H, Yang B, Zhao Y, Wei L, Chen Z J Pers Med. 2023; 13(1).

PMID: 36675702 PMC: 9865077. DOI: 10.3390/jpm13010041.

Immunosuppressive Drugs in Liver Transplant: An Insight.

Panackel C, Mathew J, Fawas N M, Jacob M J Clin Exp Hepatol. 2022; 12(6):1557-1571.

PMID: 36340316 PMC: 9630030. DOI: 10.1016/j.jceh.2022.06.007.

Clinical relevance of donor-specific human leukocyte antigen antibodies after pediatric liver transplantation.

Liu W, Wang K, Xiao Y, Liu C, Gao W, Li D Exp Ther Med. 2021; 22(2):867.

PMID: 34194545 PMC: 8237393. DOI: 10.3892/etm.2021.10299.

References

Wilson C, Agarwal K, Carter V, Burt A, Hubscher S, Talbot D . Late humoral rejection in a compliant ABO-compatible liver transplant recipient. Transplantation. 2006; 82(7):988-9. DOI: 10.1097/01.tp.0000229939.85412.27. View

OLeary J, Kaneku H, Susskind B, Jennings L, Neri M, Davis G . High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection Postliver transplant. Am J Transplant. 2011; 11(9):1868-76. PMC: 4412604. DOI: 10.1111/j.1600-6143.2011.03593.x. View

Musat A, Agni R, Wai P, Pirsch J, Lorentzen D, Powell A . The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant. 2011; 11(3):500-10. PMC: 3357120. DOI: 10.1111/j.1600-6143.2010.03414.x. View

Watson R, Kozlowski T, Nickeleit V, Woosley J, Schmitz J, Zacks S . Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation. Am J Transplant. 2006; 6(12):3022-9. DOI: 10.1111/j.1600-6143.2006.01554.x. View

Flechner S, Fatica R, Askar M, Stephany B, Poggio E, Koo A . The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation. 2010; 90(12):1486-92. DOI: 10.1097/TP.0b013e3181fdd9b0. View

Walsh R, Everly J, Brailey P, Rike A, Arend L, Mogilishetty G . Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation. 2010; 89(3):277-84. DOI: 10.1097/TP.0b013e3181c6ff8d. View

Ali S, Ormsby A, Shah V, Segovia M, Kantz K, Skorupski S . Significance of complement split product C4d in ABO-compatible liver allograft: diagnosing utility in acute antibody mediated rejection. Transpl Immunol. 2011; 26(1):62-9. DOI: 10.1016/j.trim.2011.08.005. View

Morioka D, Togo S, Kumamoto T, Takeda K, Matsuo K, Inayama Y . Six consecutive cases of successful adult ABO-incompatible living donor liver transplantation: a proposal for grading the severity of antibody-mediated rejection. Transplantation. 2008; 85(2):171-8. DOI: 10.1097/TP.0b013e31815e9672. View

Sakashita H, Haga H, Ashihara E, Wen M, Tsuji H, Miyagawa-Hayashino A . Significance of C4d staining in ABO-identical/compatible liver transplantation. Mod Pathol. 2007; 20(6):676-84. DOI: 10.1038/modpathol.3800784. View

10.

Lunz J, Ruppert K, Cajaiba M, Isse K, Bentlejewski C, Minervini M . Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring?. Am J Transplant. 2011; 12(1):171-82. DOI: 10.1111/j.1600-6143.2011.03786.x. View

11.

Colvin R . C4d in liver allografts: a sign of antibody-mediated rejection?. Am J Transplant. 2006; 6(3):447-8. DOI: 10.1111/j.1600-6143.2006.01245.x. View

12.

Takemoto S, Zeevi A, Feng S, Colvin R, Jordan S, Kobashigawa J . National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant. 2004; 4(7):1033-41. DOI: 10.1111/j.1600-6143.2004.00500.x. View

13.

Chan K, Lee C, Wu T, Lee C, Chen T, Lee W . Clinical perspective of acute humoral rejection after blood type-compatible liver transplantation. Transplantation. 2011; 91(5):e29-30. DOI: 10.1097/TP.0b013e318208138c. View

14.

Kamar N, Lavayssiere L, Muscari F, Selves J, Guilbeau-Frugier C, Cardeau I . Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation. World J Gastroenterol. 2009; 15(27):3426-30. PMC: 2712906. DOI: 10.3748/wjg.15.3426. View

15.

Kozlowski T, Rubinas T, Nickeleit V, Woosley J, Schmitz J, Collins D . Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl. 2011; 17(4):357-68. DOI: 10.1002/lt.22233. View

16.

Ratner L, Phelan D, Brunt E, Mohanakumar T, Hanto D . Probable antibody-mediated failure of two sequential ABO-compatible hepatic allografts in a single recipient. Transplantation. 1993; 55(4):814-9. DOI: 10.1097/00007890-199304000-00025. View

17.

Raut V, Uemoto S . Management of ABO-incompatible living-donor liver transplantation: past and present trends. Surg Today. 2011; 41(3):317-22. DOI: 10.1007/s00595-010-4437-3. View

18.

. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology. 1997; 25(3):658-63. DOI: 10.1002/hep.510250328. View

19.

Everly M, Everly J, Susskind B, Brailey P, Arend L, Alloway R . Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008; 86(12):1754-61. DOI: 10.1097/TP.0b013e318190af83. View

20.

Rostron A, Carter V, Mutunga M, Cavanagh G, OSuilleabhain C, Burt A . A case of acute humoral rejection in liver transplantation: successful treatment with plasmapheresis and mycophenolate mofetil. Transpl Int. 2005; 18(11):1298-301. DOI: 10.1111/j.1432-2277.2005.00200.x. View